Evidence map›Paper›PMID 31849493›Full record

ArticleOncoTargets and therapy2019

Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report.

Ling Lin, Hongfei Ge, Zhengqing Yan, Guoqiang Wang, Xiaomai Wu, Dongqing Lv

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Targeting HER2 genomic alterations in non-small cell lung cancer.Journal of the National Cancer Center · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ling LinDepartment of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, People's Republic of China.
Hongfei GeDepartment of Cardiothoracic Surgery, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, People's Republic of China.
Zhengqing YanThe Medical Department, 3D Medicines Inc., Shanghai 201114, People's Republic of China.
Guoqiang WangThe Medical Department, 3D Medicines Inc., Shanghai 201114, People's Republic of China.
Xiaomai WuDepartment of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, People's Republic of China.ORCID 0000-0002-3115-3988
Dongqing LvDepartment of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, People's Republic of China.
Wenzhou Medical University · CNShanghai Medical Information Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCASE PRESENTATION: We present a 63-year-old male with a long smoking history, who was diagnosed with stage IV squamous cell lung cancer. After the failures of two lines of treatment with carboplatin plus gemcitabine and nidaplatin plus docetaxel, in turn, the patient received a next-generation sequencing of circulating tumor DNA to seek for potential treatment opportunities. A

conclusionThis is the first case report describing a NSCLC patient harboring a rare

Indexed as

afatinibHER2 R896Gnext generation sequencingnon-small cell lung cancer

Identifiers

PMID31849493
PMCPMC6913761
OpenAlexW2995955849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.